Recombinant activated factor VII in a patient with intracranial hemorrhage and severe thrombocytopenia.

Publication/Presentation Date

10-1-2021

Abstract

Hemorrhage in patients with hematologic malignancies is often difficult to manage as many of these patients also have coagulopathy and thrombocytopenia of varying severity. Recombinant factor VIIa is a FDA-approved agent for management of bleeding in hemophilia patients with inhibitors. Use of recombinant FVIIa has also been used as a last resort in various clinical settings such as trauma, alveolar hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage for control of bleeding with variable outcomes. This paper presents a case of recombinant FVIIa administration in a patient with multiple myeloma and profound transfusion refractory thrombocytopenia suffering from traumatic subdural hematoma.

Volume

9

Issue

10

First Page

04788

Last Page

04788

ISSN

2050-0904

Disciplines

Medicine and Health Sciences

PubMedID

34659753

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Link to Full Text

Share

COinS